Form 4: Theriva Biologics Director Acquires Stock Options

Theriva Biologics Director Jeffrey Alan Wolf acquired 75,000 stock options with an exercise price of $0.241, vesting monthly over 12 months starting February 1, 2026.

Summary

• Jeffrey Alan Wolf, a Director of Theriva Biologics, Inc. (TOVX), reported the acquisition of 75,000 stock options.
• The stock options have an exercise price of $0.241 per share.
• The transaction date for these options was January 5, 2026.
• These options grant the right to buy 75,000 shares of common stock.
• The options begin vesting pro rata on a monthly basis over 12 months, starting February 1, 2026.
• The expiration date for these stock options is January 4, 2033.
• Following this transaction, Jeffrey Alan Wolf beneficially owns 75,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed as a positive signal, indicating insider confidence in the company's future prospects. However, it is a routine compensation event and not a major operational or financial announcement.

Positives

• A Director acquiring stock options can signal confidence in the company's future performance and alignment of interests with shareholders.

Future Outlook

The acquisition of stock options by a director, with a vesting schedule extending over 12 months, implies a long-term commitment and potential belief in the company's future growth and stock appreciation over that period.

Management Comments

• The acquisition of 75,000 stock options by Director Jeffrey Alan Wolf, with an exercise price of $0.241, reflects a direct investment in the company's future performance.

Industry Context

Insider transactions, such as the acquisition of stock options by a director, are common occurrences in publicly traded companies across all industries. These filings provide transparency into management's direct financial interest in the company's stock performance, often viewed by investors as a signal of confidence, particularly in the biotechnology sector where long-term development cycles are prevalent.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice in many industries, including biotechnology, aligning management incentives with shareholder value creation.
• The vesting schedule of 12 months is a common period designed to retain key personnel and incentivize sustained performance, comparable to similar grants observed at companies like BioNTech or Moderna for their executives and board members.

Related Party Transactions

• The acquisition of stock options by Director Jeffrey Alan Wolf from Theriva Biologics, Inc. constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the director's acquisition of options as a positive indicator of management's belief in the company's future value, potentially influencing investor sentiment.
• The vesting schedule incentivizes the director to contribute to the company's long-term success, aligning their interests with those of other stakeholders.

Next Steps

• The stock options will vest pro rata on a monthly basis over 12 months, commencing February 1, 2026.

Key Dates

Keywords

Theriva Biologics, TOVX, Stock Options, Insider Transaction, Form 4, Director, Equity Acquisition